aTyr Pharma is a biotherapeutics company engaged in the discovery and clinical development of medicines based on immunological pathways. Co.'s primary focus is on ATYR1923, a clinical stage product candidate which binds to the neuropilin-2 (NRP2) receptor and is designed to down regulate immune engagement in interstitial lung diseases (ILDs). Co. is developing ATYR1923 as a potential therapeutic for patients with ILDs, a group of immune-mediated disorders that cause progressive fibrosis of the lung tissue. Co. is investigating NRP2 receptor biology to identify new product candidates for a variety of disease settings, including cancer, inflammation, and lymphangiogenesis. The LIFE stock yearly return is shown above.
The yearly return on the LIFE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LIFE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|